NCT06909565ClinicalTrials.gov
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)
In breve
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on…
Fase 46000 partecipanti ricercati153 centri1 paese
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT06909565Apri questa scheda su ClinicalTrials.govSincronizzato l’altro ieri
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-04-03; recorded start 2025-07-23
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 475 other studies in this databaseCounted from the lead sponsor named in the record (Duke University)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 4 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 115 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study: 6,000 participants (target), run at 153 sites.
How this score is built
- Enrolment36/40
6,000 participants (target)
- Site count23/25
115 sites
- Country count0/15
Single country
- Planned duration9/10
Planned over about 53 months
- Sponsor scale10/10
Duke University has led 456 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Patologie
- Percutaneous Coronary Intervention
- Peripheral Endovascular Intervention
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – Nessun massimo |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 4 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | PREVENTION |
| Mascheramento | QUADRUPLE (4) |
| Arruolamento | 6000 partecipanti ricercati |
Sponsor e collaboratori
- Duke University Sponsor
- Novartis Pharmaceuticals Collaboratori
- Colorado Prevention Center Collaboratori
- Mount Sinai Hospital, New York Collaboratori
Bracci e interventi
- Inclisiran SodiumACTIVE_COMPARATOR
Inclisiran sodium 300 mg subcutaneous injection
- PlaceboPLACEBO_COMPARATOR
Normal saline 1.5 ml subcutaneous injection
Interventi
- Farmaco Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
300 mg (equivalent to 284 mg inclisiran) in 1.5 mL subcutaneous injection at Day 0; Day 90; \& every 6 months thereafter
- Farmaco Normal Saline (Placebo)
Normal saline placebo subcutaneous injection given at Day 0, Day 90; \& every 6 months thereafter
Esiti misurati
Esito primario
Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularization
MACEs include CHD death, non-fatal MI, ischemic stroke, ALI, major (above the ankle) amputation of vascular etiology, clinically driven coronary and limb revascularization.
Orizzonte temporale From randomization to first occurrence of MACE (up to approximately 4 years)
Esito primario
Total number of major adverse limb events (MALE) after endovascular revascularization
MALEs consist of ALI, major amputation of vascular etiology, clinically driven lower extremity peripheral revascularization.
Orizzonte temporale From randomization to first occurrence of MALE (up to approximately 4 years)
Esito secondario
Number of participants with cardiovascular (CV) death
Orizzonte temporale From randomization to CV death (up to approximately 4 years)
Esito secondario
Number of participants with all cause death
Orizzonte temporale From randomization to all cause death (up to approximately 4 years)
Esito secondario
Number of participants with venous thromboembolic events (VTE)
Orizzonte temporale From randomization to first VTE (up to approximately 4 years)
Date
| Data di inizio | 23 luglio 2025 (effettiva) |
|---|---|
| Conclusione primaria | 1 ottobre 2029 (stimata) |
| Conclusione | 1 dicembre 2029 (stimata) |
| Prima pubblicazione | 3 aprile 2025 (effettiva) |
| Ultimo aggiornamento | 16 novembre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | luglio 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
149 centri stanno reclutando
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Capital Cardiology Associates | Albany | New York | In reclutamento |
| Presbyterian Heart Group | Albuquerque | New Mexico | In reclutamento |
| Advanced Cardiovascular LLC | Alexander City | Alabama | In reclutamento |
| Amarillo Heart Clinical Research Institute, Inc. | Amarillo | Texas | In reclutamento |
| PharmaTex Research | Amarillo | Texas | In reclutamento |
| AnMed Health Medical Center | Anderson | South Carolina | In reclutamento |
| Asheville Cardiology Associates Research Department | Asheville | North Carolina | In reclutamento |
| University of Colorado Anschutz Medical Campus | Aurora | Colorado | In reclutamento |
| Austin Heart | Austin | Texas | In reclutamento |
| IMS Cardiology | Avondale | Arizona | In reclutamento |
| Northern Light Eastern Maine Medical Center | Bangor | Maine | In reclutamento |
| St. Luke's University Health Network | Bethlehem | Pennsylvania | In reclutamento |
| Pacific Oaks Medical Group | Beverly Hills | California | In reclutamento |
| Cardiology, PC | Birmingham | Alabama | In reclutamento |
| Grace Research, LLC | Bossier City | Louisiana | In reclutamento |
| Bridgeport Hospital | Bridgeport | Connecticut | In reclutamento |
| Advanced Heart Care LLC | Bridgewater | New Jersey | In reclutamento |
| Trinity Medical WNY, PC | Buffalo | New York | In reclutamento |
| Sisters of Charity Hospital | Buffalo | New York | In reclutamento |
| Capital Area Research LLC | Camp Hill | Pennsylvania | In reclutamento |
| Aultman Hospital | Canton | Ohio | In reclutamento |
| Wellspan Chambersburg Hospital | Chambersburg | Pennsylvania | In reclutamento |
| Mecklenburg Heart Specialists | Charlotte | North Carolina | In reclutamento |
| Novant Health Clinical Research/Heart & Vascular Institute | Charlotte | North Carolina | In reclutamento |
| Atrium Health-Sanger Heart and Vascular Institute | Charlotte | North Carolina | In reclutamento |
| University of Illinois Chicago | Chicago | Illinois | In reclutamento |
| Cardiovascular Institute of San Diego | Chula Vista | California | In reclutamento |
| Clearwater Cardiovascular Consultants | Clearwater | Florida | In reclutamento |
| BayCare Medical Group | Clearwater | Florida | In reclutamento |
| MedStar Southern Maryland Hospital Center | Clinton | Maryland | In reclutamento |
| University of Missouri Health Care | Columbia | Missouri | In reclutamento |
| John Muir Medical Center - Concord Campus | Concord | California | In reclutamento |
| Javara inc. | Conroe | Texas | Ritirato |
| Pioneer Clinical Studies | Coral Gables | Florida | In reclutamento |
| Valley Clinical Trials | Covina | California | Ritirato |
| Louisiana Heart Center | Covington | Louisiana | In reclutamento |
| Nuvance Health- Danbury Hospital | Danbury | Connecticut | In reclutamento |
| Cardiology Research Associates | Daytona Beach | Florida | In reclutamento |
| Arrow Clinical Trails | Daytona Beach | Florida | In reclutamento |
| Essentia Health-SMMC | Duluth | Minnesota | In reclutamento |
| Aspirus Saint Luke's Hospital | Duluth | Minnesota | In reclutamento |
| Midwest Cardiovascular Research and Education Foundation | Elkhart | Indiana | In reclutamento |
| Cardiovascular Associates of the Delaware Valley | Elmer | New Jersey | In reclutamento |
| Aurora Denver Cardiology Associates - Englewood | Englewood | Colorado | In reclutamento |
| Javara Inc. | Fayetteville | North Carolina | In reclutamento |
| Advanced Heart and Vascular Institute Of Hunterdon | Flemington | New Jersey | In reclutamento |
| Northeast Georgia Heart Center, PC | Gainesville | Georgia | In reclutamento |
| Stern Cardiovascular Center | Germantown | Tennessee | In reclutamento |
| Thrive Clinical Research Group | Glendora | California | In reclutamento |
| CHI Health Nebraska Heart | Grand Island | Nebraska | In reclutamento |
Nella scheda del registro sono indicati altri 103 centri.
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 16 novembre 2026
Centro aggiunto
4 sites added (153 total)
149153
- 29 ottobre 2026
Centro aggiunto
2 sites added (149 total)
147149
- 23 ottobre 2026
Centro aggiunto
2 sites added (147 total)
145147
- 19 ottobre 2026
Centro aggiunto
3 sites added (145 total)
142145
- 5 ottobre 2026
Centro aggiunto
1 site added (142 total)
141142
- 28 settembre 2026
Centro aggiunto
2 sites added (141 total)
139141
- 22 settembre 2026
Centro aggiunto
1 site added (139 total)
138139
- 15 settembre 2026
Centro aggiunto
2 sites added (138 total)
136138
- 28 agosto 2026
Centro aggiunto
3 sites added (136 total)
133136
- 18 agosto 2026
Centro aggiunto
8 sites added (133 total)
125133
- 5 agosto 2026
Centro aggiunto
10 sites added (125 total)
115125